Skip to main content

Table 1 Patient characteristicsa

From: Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain

Variable

Number

%

Breast cancer type

  

   Ductal

98

82

   Lobular

10

8

   Ductal/lobular

2

2

   Uncertain

4

3

   Other

5

4

Grade

  

   1

6

5

   2

41

34

   3

56

47

   Unknown

17

14

ER

  

   Positive

51

42

   Negative

69

57

PR

  

   Positive

40

34

   Negative

78

65

   Not determined

1

1

HER2

  

   Positive (IHC3+)

51

42

   Positive (IHC2+ and FISH+)

6

5

   Negative

62

52

   Not determined

1

1

Chemotherapy before brain metastases

  

   Yes, adjuvant, neoadjuvant

47

39

   Yes, for metastatic disease

9

7

   Yes, a combination thereof

47

39

   No

8

7

   Unknown

9

7

Endocrine therapy before brain metastasesb

  

   Yes, adjuvant, neoadjuvant

31

26

   Yes, for metastatic disease

5

4

   Yes, a combination thereof

13

11

   No

66

55

   Unknown

5

4

Trastuzumab before brain metastasesc

  

   Yes

30

53

   No

25

43

   Unknown

2

3

Chemotherapy after brain surgery

  

   Yes

57

47

   No

47

39

   Unknown

16

13

Endocrine therapy after brain surgeryb

  

   Yes

21

17

   No

86

72

   Unknown

13

11

Anti-HER2 therapy after brain surgeryc

  

   Trastuzumab

9

16

   Lapatinib

7

12

   Sequentially both

3

5

Type of first progression

  

   Local

2

2

   Regional

9

7

   Distant

106

88

   Combined local regional and/or distant

1

1

   Unknown

1

2

Dominant site of metastatic diseased

  

   Soft tissue

3

2

   Bone

5

4

   Visceral

110

92

   Unknown

2

2

Age at breast cancer diagnosis (mean (range) years)

49 (26-80)

Age at brain metastasis surgery (mean (range) years)

52 (29-83)

  1. aPercentages may not sum to 100 because of rounding to full numbers; btamoxifen, aromatase inhibitors, or tamoxifen and aromatase inhibitors; cin HER2-positive patients (IHC3+ or IHC2+ and FISH+); dcategory of worst prognosis irrespective of the extent, in order: soft tissue, bone, visceral; see Materials and methods. Number of patients, 120. ER, estrogen receptor; HER2, epidermal growth factor receptor; PR, progesterone receptor; WBRT, whole-brain radiotherapy.